Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 297-301

  Bohnenstengel, F ^a   Hofmann, U ^a   Eichelbaum, M ^a   Kroemer, H K ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

cyclophosphamide; CYP 3A4; side chain oxidation; dechloroethylcyclophosphamide

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; DECHLOROETHYLCYCLOPHOSPHAMIDE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT;

ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION;

EID: 0030444353     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050201     Document Type: Article

References (22)

1. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23:115-129
2. Fenselau C, Kan MNN, Rao SS, Myles A, Friedman OM, Colvin M (1977) Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 37: 2538-2543
3. Domeyer BE, Sladek NE (1980) Metabolism of 4-hydroxycyclophosphamide/ald phosphamide in vitro. Biochem Pharmacol 29:2903-2912
4. Ruzicka JA, Ruenitz PC (1992) Cytochrom P-450 mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metab Dispos 20:770-772
5. Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet II No. 8517:1219-1220
6. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637
7. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423
8. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR (1995) Cyclophosphamide metabolism in children. Cancer Res 55:803-809
9. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson DJ, Beaune PH, Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47:1157-11631
10. Bohnenstengel F, Johnson S, Hofmann U, Eichelbaum M, Kroemer HK (1995) Direct gas chromatographic determination of dechloroethylcyclophosphamide following microsomal incubation of cyclophosphamide. J Chromatogr B 672:271-276
11. Meier PJ, Müller HK, Dick B, Meyer UA (1983) Hepatic monooxygenase activities in subjects with genetic defect in drug oxidation. Gastroenterology 85:682-692
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
13. Omura T, Sato R (1964) The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-2378
14. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1995) Keto conazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 25:261-270
15. Kunze KL, Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656
16. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br J Clin Pharmacol 29:651-663
17. Kivistö KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anti-cancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-530
18. Boddy AV, Furtun Y, Sardas S, Sardas O, Idle JR (1992) Interindividual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Nat Cancer Inst 84:1744-1748
19. Murray M, Butler AM, Stupans I (1994) Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6β-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J Pharmacol Exp Ther 270:645-649
20. Zorsky PE, Perkins JB (1993) Optimizing high-dose therapy-using pharmacokinetic principles. Semin Oncol 20:2-18
21. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei III E (1992) Cyclophosphamide pharmacokinetic: correlation with cardiac toxicity and tumor response. J Clin Oncol 10:995-1000
22. Busse D, Bohnenstengel F, Eichelbaum M, Fischer P, Kroemer HK, Schumacher K, Schweizer E, Busch FW (1996) Pharmacokinetics and metabolism of cyclophosphamide during "conventional" and "high dose" chemotherapy. Naunyn-Schmiedeberg's Arch Pharmacol 353 Suppl:R147